BACKGROUND: We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carcinoma (HNSCC). METHODS: The in vitro effects of vandetanib (ZACTIMA) were assessed in 2 HNSCC cell lines on cell growth, apoptosis, receptor and downstream signaling molecule expression, and phosphorylation levels. We assessed in vivo effects of vandetanib and/or paclitaxel by measuring tumor cell apoptosis, endothelial cell apoptosis, microvessel density, tumor size, and animal survival. RESULTS: In vitro, vandetanib inhibited the phosphorylation of EGFR and its downstream targets in HNSCC cells and inhibited proliferation and induced apoptosis of HNSCC cells and extended survival and inhibited tumor growth in nude mice orthotopically injected with human HNSCC. CONCLUSION: Vandetanib has the potential to be a novel molecular targeted therapy for HNSCC.
BACKGROUND: We investigated the effects of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2) and epidermal growth factor receptor (EGFR), alone and in combination with paclitaxel in an orthotopic mouse model of human head and neck squamous cell carcinoma (HNSCC). METHODS: The in vitro effects of vandetanib (ZACTIMA) were assessed in 2 HNSCC cell lines on cell growth, apoptosis, receptor and downstream signaling molecule expression, and phosphorylation levels. We assessed in vivo effects of vandetanib and/or paclitaxel by measuring tumor cell apoptosis, endothelial cell apoptosis, microvessel density, tumor size, and animal survival. RESULTS: In vitro, vandetanib inhibited the phosphorylation of EGFR and its downstream targets in HNSCC cells and inhibited proliferation and induced apoptosis of HNSCC cells and extended survival and inhibited tumor growth in nude mice orthotopically injected with human HNSCC. CONCLUSION: Vandetanib has the potential to be a novel molecular targeted therapy for HNSCC.
Authors: Jeffrey N Myers; F Christopher Holsinger; Samar A Jasser; B Nebiyou Bekele; Isaiah J Fidler Journal: Clin Cancer Res Date: 2002-01 Impact factor: 12.531
Authors: Teresa Troiani; Natalie J Serkova; Daniel L Gustafson; Thomas K Henthorn; Owen Lockerbie; Andrea Merz; Michael Long; Mark Morrow; Fortunato Ciardiello; S Gail Eckhardt Journal: Clin Cancer Res Date: 2007-11-01 Impact factor: 12.531
Authors: J Hun Hah; Mei Zhao; Curtis R Pickering; Mitchell J Frederick; Genevieve A Andrews; Samar A Jasser; David R Fooshee; Zvonimir L Milas; Chad Galer; Daisuke Sano; William N William; Edward Kim; John Heymach; Lauren A Byers; Vali Papadimitrakopoulou; Jeffrey N Myers Journal: Head Neck Date: 2014-03-20 Impact factor: 3.147
Authors: David M Neskey; Abdullah A Osman; Thomas J Ow; Panagiotis Katsonis; Thomas McDonald; Stephanie C Hicks; Teng-Kuei Hsu; Curtis R Pickering; Alexandra Ward; Ameeta Patel; John S Yordy; Heath D Skinner; Uma Giri; Daisuke Sano; Michael D Story; Beth M Beadle; Adel K El-Naggar; Merrill S Kies; William N William; Carlos Caulin; Mitchell Frederick; Marek Kimmel; Jeffrey N Myers; Olivier Lichtarge Journal: Cancer Res Date: 2015-01-29 Impact factor: 12.701
Authors: Daisuke Sano; Tong-Xin Xie; Thomas J Ow; Mei Zhao; Curtis R Pickering; Ge Zhou; Vlad C Sandulache; David A Wheeler; Richard A Gibbs; Carlos Caulin; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-09-08 Impact factor: 12.531
Authors: Daisuke Sano; Fumihiko Matsumoto; David R Valdecanas; Mei Zhao; David P Molkentine; Yoko Takahashi; Ehab Y Hanna; Vali Papadimitrakopoulou; John Heymach; Luka Milas; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-02-24 Impact factor: 12.531
Authors: Sandrina Körner; Tillman Pick; Florian Bochen; Silke Wemmert; Christina Körbel; Michael D Menger; Adolfo Cavalié; Jan-Philipp Kühn; Bernhard Schick; Maximilian Linxweiler Journal: Front Physiol Date: 2022-08-15 Impact factor: 4.755